The Series A & B Investor Daily Brief
Get the latest updates on U.S. startups securing Series A and B funding, featuring key deals, top investors, and emerging industries shaping the future.
Key Series A Rounds: Allink, Celosia, Constrafor, Roon, and Doron Therapeutics
Episode 5 explores a diverse array of Series A funding rounds, starting with Allink Biotherapeutics securing $42 million, providing insights into their biotherapeutic advancements. Celosia Therapeutics' Series A funding is highlighted for its focus on ALS gene therapy. The episode also features Constrafor's impressive $264 million Series A, driving innovation in the construction industry. Additionally, Roon's Series A funding is covered, emphasizing expansion in women's health information, alongside Doron Therapeutics' Series A earmarked for Phase 3 clinical studies in osteoarthritis.
Key Points
- Allink Biotherapeutics raised $42 million in Series A funding to advance its bispecific antibody and ADC therapeutics for oncology and immunology.
- Celosia Therapeutics secured $16.75 million in Series A funding to develop its gene therapy for ALS, positioning Australia at the forefront of global ALS research.
- Constrafor closed a $264 million Series A funding round to revolutionize construction finance technology, addressing key industry challenges like tight margins and cash flow constraints.
Speakers
Michelle
Host • 100%
Chapters
| 0:00 | |
| 0:16 | |
| 3:21 | |
| 5:04 | |
| 8:19 | |
| 11:34 | |
| 14:02 |
Transcript
Loading transcript...
- / -